骨髓增生异常综合征临床研究(1)
 |
| 第1页 |
参见附件(1485KB，2页)。
【摘要】 目的 探讨沙利度胺、环孢素A及亚砷酸联合治疗骨髓增生异常综合征的临床疗效。方法 将27例骨髓增生异常综合征患者随机分为对照组13例和治疗组14例。对照组予以雄激素、全反式维甲酸或小剂量化疗、干扰素等治疗6个月。治疗组采用沙利度胺、环孢素A及亚砷酸联合治疗方案,依患者耐受情况选用维持剂量并连用3~6个月。比较2组的临床疗效和不良反应。结果 治疗组和对照组总有效率分别为78.57%(11/14)和46.15%(6/13)。2组总有效率比较,差异有统计学意义(P<0.05)。治疗组中不良反应主要为剂量依赖性和可逆性,经对症处理后好转。大多数患者耐受良好,无治疗相关性死亡。结论 沙利度胺、环孢素A及亚砷酸联合治疗骨髓增生异常综合征疗效确切,不良反应轻微,患者可耐受。
【关键词】骨髓增生异常综合征;沙利度胺;环孢素A;亚砷酸
Clinical study of myelodysplastic syndrome
TIAN Ying.Henan Province Shangqiu first People’s Hospital Blood branch 476100,China
【Abstract】 Objective To investigate thalidomide,cyclosporine A,and arsenious acid combined treatment of myelodysplastic syndrome clinical efficacy.Methods 27 patients with myelodysplastic syndrome were randomly divided into control group 13 cases and 14 cases of treatment group.The control group to be male hormones,all trans retinoic acid or a small dose chemotherapy,interferon and other treatment for 6 months.The treatment group were treated with thalidomide,cyclosporine A,and arsenious acid combined treatment programs,according to patient tolerance,and used in conjunction to choose a maintenance dose of 3 to 6 months.Comparison of two groups of clinical efficacy and adverse reactions.Results The treatment group and control group,the total effective rate was 78.57%(11/14)and 46.15%(6/13).The total effective rate,the difference was significant(P<0.05).The treatment group,adverse reactions and reversible dose dependent manner mainly by symptomatic improvement after treatment.It was well tolerated in most patients,no treatment related death.Conclusion Thalidomide,cyclosporine A,and arsenious acid combined treatment of myelodysplastic syndrome accurate,adverse reactions are mild,the patient can be tolerated.
【Key words】Myelodysplastic syndrome; Thalidomide; Cyclosporin A; Arsenic trioxide
骨髓增生异常综合征(myelodysplastic syndromes,MDS)是一组以难治性全血细胞减少,并有血细胞质、量异常及高风险发展成急性白血病为特征的恶性克隆造血干细胞病。治疗MDS的主要目标是减少因贫血、白细胞减少及血小板下降引起的并发症,提高患者的生存质量[1]。我院2005年12月至2009年4月采用沙利度胺、环孢素A(CsA)及亚砷酸联合治疗方案治疗MDS14例,取得理想效果。现报告如下。
1 资料与方法
1.1 一般资料 本组MDS患者27例,男19例,女8例;年龄35~71岁,平均48.4岁;根据张之南等主编的《血液病诊断与疗效标准》明确诊断[2]。采用FAB诊断和分型标准:其中难治性贫血(RA)14例、环形铁粒幼细胞增多性难治性贫血(RAS)5例、难治性贫血伴原始细胞增多(RAEB)7例、转变中的难治性贫血伴原始细胞增多(RAEB T)1例 ......
您现在查看是摘要介绍页，详见PDF附件(1485KB，2页)。